DanielaEMateiMD

Oncology • Chicago, IL

Gynecologic Cancer, Hematologic Oncology

Associate Professor, Medicine, Indiana University School of Medicine

Join to view full profile

Dr. Matei is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Matei's full profile

Already have an account?

Office
303 E Superior Lurie 4-107
Chicago, IL 60610
Phone+1 312-503-4853

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 1997 - 1999
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 1993 - 1996
Carol Davila University of Medicine and PharmacyClass of 1992

Certifications & Licensure

CA State Medical License 1996 - Present
IL State Medical License 2015 - 2026
IN State Medical License 2002 - 2017
American Board of Internal Medicine Medical Oncology

Clinical Trials

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Start of enrollment: 2004 Oct 01
Completed
Phase 2
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer Start of enrollment: 2003 Dec 01
Completed
Phase 2
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer Start of enrollment: 2007 Sep 01
Terminated
Phase 1, Phase 2
Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors Start of enrollment: 2008 Jan 23
Completed
Phase 1
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer Start of enrollment: 2011 Nov 01
Terminated
Phase 1
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients Start of enrollment: 2012 Oct 01
Withdrawn
Phase 1, Phase 2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 Apr 29
Active, not recruiting
Phase 2
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA Start of enrollment: 2014 Sep 01
Unknown status
Phase 2
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2016 Nov 11
Completed
Phase 2
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Start of enrollment: 2019 Dec 10
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

153 citations
N-linked Glycan Structures and Their Expressions Change in the Blood Sera of Ovarian Cancer Patients
William R. Alley, Jacqueline A. Vasseur, John A. Goetz, Martin Svoboda, Benjamin F. Mann
Journal of Proteome Research. 2012-04-06
37 citations
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A. Matulonis, Julie Lee, Brian Lasonde, William P. Tew, Afra Yehwalashet
European Journal of Cancer. 2013-01-01
213 citations
NF-κB-HOTAIR Axis Links DNA Damage Response, Chemoresistance and Cellular Senescence in Ovarian Cancer
Ali R. Özeş, David F.B. Miller, Osman Nidai Ozes, Fang Fang, Yunlong Liu
Oncogene. 2016-10-13

Journal Articles

Epigenetic Targeting of Ovarian Cancer Stem Cells
6) Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Nephew KP, Matei D, Cancer Research, 7/2014

Press Mentions

Remember When Princess Diana Raised Money for Northwestern Cancer Center?February 5th, 2021
ZIP4 Is a Novel Cancer Stem Cell Marker in High-Grade Serous Ovarian CancerDecember 9th, 2020
Northwestern Scientists Awarded Top Honors for Achievement in Clinical ResearchApril 15th, 2020
Join now to see all

Grant Support

Role Of Tissue Transglutaminase In Ovarian CancerVeterans Affairs2011–2012
Transglutaminase Modulated Tumor-Stroma Interaction In Pancreatic CancerNational Cancer Institute2011
A Low-Dose Decitabine Strategy For Restoring Ovarian Cancer SensitivityNational Cancer Institute2008–2009
A Phase I Trial Of Lapatinib In Combination With Carboplatin In Patients With PLNational Center For Research Resources2007–2008